Table 2.
A larger proportion of the patients with nocturnal nasal obstruction at follow‐up had nocturnal sweating, nocturnal gastroesophageal reflux, insomnia and impaired physical quality of life
| Never (n = 418) | Only at baseline (n = 134) | Only at 2‐year follow‐up (n = 52) | Both at baseline and at 2‐year follow‐up (n = 124) | p‐value for group difference | |
|---|---|---|---|---|---|
| Underwent nasal surgery during the study | 12% | 25% | 10% | 15% | 0.01 |
| Nocturnal sweating, ≥ 3 × per week, 2 years | 13% | 14% | 62% | 25% | 0.007 |
| Nocturnal gastroesophageal reflux, ≥ 1 × per week, 2 years | 5% | 14% | 8% | 15% | 0.002 |
| Daytime sleepiness (ESS), 2 years | 8.4 ± 4.6 | 8.6 ± 4.7 | 9.7 ± 4.2 | 8.8 ± 4.9 | 0.17 |
| Initial insomnia, ≥ 3 × per week, 2‐year follow‐up | 9% | 16% | 10% | 18% | 0.01 |
| Middle insomnia, ≥ 3 × per week, 2 years | 29% | 39% | 57% | 44% | 0.001 |
| Late insomnia, ≥ 3 × per week, 2 years | 18% | 31% | 35% | 30% | <0.001 |
| SF‐12, Mental part, 2 years | 51.7 ± 9.9 | 50.2 ± 10.8 | 49.1 ± 10.0 | 50.2 ± 10.5 | 0.16 |
| SF‐12, Physical part, 2 years | 43.4 ± 11.3 | 44.2 ± 10.7 | 42.4 ± 11.9 | 39.9 ± 11.4 | 0.01 |
| Number of days on PAP | 595.0 ± 241.1 | 593.2 ± 235.3 | 592.7 ± 223.9 | 573.4 ± 251.7 | 0.10 |
| Hours of PAP use, last 28 days before 2 years (fu007; n = 203, missing 215) Objective data | 6.17 ± 2.22 | 6.49 ± 1.67 | 5.47 ± 2.42 | 6.60 ± 1.88 | 0.10 |
| Late quitters (n = 17) | 2% | 2% | 4% | 3% | 0.41 |
| Early quitters (n = 131) | 18% | 19% | 15% | 23% | |
| Partial users (n = 199) | 14% | 8% | 23% | 15% | |
| Full users (n = 480) | 66% | 71% | 58% | 63% |
ESS, Epworth Sleepiness Scale; PAP, positive airway pressure; SF‐12, the 12‐Item Short‐Form Health Survey, a smaller version of the SF‐36v2 Health Survey, measuring quality of life.
Significance given in bold. Mean values shown as mean ± SD and p‐values. Chi‐squared test when comparing proportions of groups here in %. Kruskal–Wallis ANOVA when comparing ordinal data. Post hoc test (Mann–Whitney U‐test): subgroup analysis comparing the groups SF‐12, Physical part, 2 years, only baseline with both baseline and follow‐up, p‐value 0.18.